Renin-angiotensin system inhibitors for patients with mild or moderate chronic kidney disease and heart failure with mildly reduced or preserved ejection fraction
- PMID: 38761975
- DOI: 10.1016/j.ijcard.2024.132190
Renin-angiotensin system inhibitors for patients with mild or moderate chronic kidney disease and heart failure with mildly reduced or preserved ejection fraction
Abstract
Background: Renin-angiotensin system inhibitors (RASI) reduce adverse cardiovascular events in patients with heart failure (HF) with left ventricular ejection fraction (LVEF) ≤40% and mild or moderate chronic kidney disease (CKD). However, RASI administration rate and its association with long-term outcomes in patients with CKD complicated by HF with LVEF >40% remain unclear.
Methods: We analyzed 1923 consecutive patients with LVEF >40% registered within the multicenter database for hospitalized HF. We assessed RASI administration rate and its association with all-cause mortality among patients with mild or moderate CKD (estimated glomerular filtration rate [eGFR]: 30-60 mL/min/1.73 m2). Exploratory subgroups included patients grouped by age (<80, ≥80 years), sex, previous HF hospitalization, B-type natriuretic peptide (higher, lower than median), eGFR (30-44, 45-59 mL/min/1.73 m2), systolic blood pressure (<120, ≥120 mmHg), LVEF (41-49, ≥50%), and mineralocorticoid receptor antagonists (MRA) use.
Results: Among patients with LVEF >40%, 980 (51.0%) had mild or moderate CKD (age: 81 [74-86] years; male, 52.6%; hypertension, 69.7%; diabetes, 25.9%), and 370 (37.8%) did not receive RASI. RASI use was associated with hypertension, absence of atrial fibrillation, and MRA use. After multivariable adjustments, RASI use was independently associated with lower all-cause mortality over a 2-year median follow-up (hazard ratio: 0.58, 95% confidence interval: 0.43-0.79, P = 0.001), and the mortality rate difference was predominantly due to cardiac death, consistent in all subgroups.
Conclusions: Approximately one-third of HF patients with mild or moderate CKD and LVEF >40% were discharged without RASI administration and demonstrated relatively guarded outcomes.
Keywords: Chronic kidney disease; Heart failure; Preserved ejection fraction; Renin-angiotensin system.
Copyright © 2024 Elsevier B.V. All rights reserved.
Similar articles
-
Association between renin-angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study.Eur Heart J. 2018 Dec 21;39(48):4257-4265. doi: 10.1093/eurheartj/ehy621. Eur Heart J. 2018. PMID: 30351407
-
Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.Drugs Aging. 2019 Dec;36(12):1123-1131. doi: 10.1007/s40266-019-00709-1. Drugs Aging. 2019. PMID: 31493202
-
Efficacy of renin-angiotensin system inhibitors for patients with heart failure with preserved ejection fraction and mild to moderate chronic kidney disease.Eur J Prev Cardiol. 2018 Aug;25(12):1268-1277. doi: 10.1177/2047487318780035. Epub 2018 May 29. Eur J Prev Cardiol. 2018. PMID: 29808753 Clinical Trial.
-
Sex differences in efficacy of pharmacological therapies in heart failure with reduced ejection fraction: a meta-analysis.ESC Heart Fail. 2022 Aug;9(4):2753-2761. doi: 10.1002/ehf2.13974. Epub 2022 May 23. ESC Heart Fail. 2022. PMID: 35603531 Free PMC article.
-
Meta-analysis of Renin-Angiotensin-aldosterone blockade for heart failure in presence of preserved left ventricular function.J Cardiovasc Pharmacol Ther. 2011 Sep-Dec;16(3-4):368-75. doi: 10.1177/1074248410391667. Epub 2010 Dec 30. J Cardiovasc Pharmacol Ther. 2011. PMID: 21193681 Review.
Cited by
-
eGFRCystatin C, difference between eGFRCystatin C and eGFRCre and heart failure: Insight from the NHANES 2001-2002 and Mendelian randomization analysis.Int J Cardiol Cardiovasc Risk Prev. 2024 Sep 27;23:200337. doi: 10.1016/j.ijcrp.2024.200337. eCollection 2024 Dec. Int J Cardiol Cardiovasc Risk Prev. 2024. PMID: 40225786 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous